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Editorial
5-Fluorouracil in colorectal cancer, a never ending story
5-Fluorouracil (FU) is one of the oldest chemothera-
peutic agents still in use. It was first synthesized by C.
Heidelberger [5] based on the rationale that tumors
would preferentially use uracil which had been put for-
ward by Rutmann [12]. The potential mechanisms of
action were unknown at this time.
This drug has played an important role in the treat-
ment of a variety of cancers and is the main stay of the
treatment of colorectal cancer. Still after so many years
of use, the best way to apply this drug is not clear. It
may vary depending on the type of primary or even the
individual tumor. FU may be given by bolus injection,
i.e., 3-5 minutes, by short infusion over 30 minutes to
several hours, by 24 hours to 48 hours infusion or by
long term infusion over one to several weeks or
months. For some of these applications, randomized
studies have been performed indicating that long term
continuous infusion of FU is superior to bolus injection
in terms of response rate, but not in terms of survival.
The assessment of these (and other) trials using a FU
bolus treatment is compromised by the fact that many
clinicians or nurses give FU by short term infusions
claiming that it would be better tolerated. Although this
has not been shown in a controlled study, it is likely that
by extending the duration of FU application even to 15
or 30 minutes, one will reduce not only toxicity but also
efficacy. This can be explained by a limited capacity of
the 5-FU degrading enzyme dehydropyrimidin-de-
hydrogenase which can be rapidly saturated following a
bolus injection allowing for more 5-FU to be anabo-
lized or activated.
In the late 1970s and early 1980s the interest in FU
has been sparked by the observation that its activity in
vitro can be improved through biochemical modulation
[3]. This has been made possible through the increasing
knowledge of the mechanisms by which FU acts. A
number of modulators have been introduced. Metho-
trexate (MTX) and folinic acid (FA) have been studied
extensively as modulators. MTX/FU and FU/FA have
only been compared in one large study [11] where
MTX/FU was given at a reduced dose intensity com-
pared to the original regimen [6] and hence was inferi-
or. Many studies have been performed comparing
MTX/FU or FU/FA with FU single agent [1,2]. These
studies provide evidence of a modulating effect of both
agents with increased response rates if equimolar doses
of FU are being used - at the expense of increased tox-
icity. Still, the responses are not long enough to pro-
foundly influence the course of the disease. It is pos-
sible that in some patients the FU plus modulator
responsive part of the tumor is eliminated leaving a
more aggressive rest that regrows even faster. The find-
ing of significantly superior times to progression and
no difference in overall survival would indicate so.
Studies trying to compare equitoxic regimens of FU
plus modulator failed to even see a significant advan-
tage of FU modulation [1]. Thus, I would challenge the
statement of the late C. Moertel in his review in New
England Journal of Medicine [9] (my letter to the editor
of New England Journal of Medicine criticising this
statement of C. Moertel has been rejected).
In this issue of Annals of Oncology, Dufour et al. lay
to rest yet another hope of FU modulation [4]. Al-
though they show a small advantage of FU plus a-inter-
feron (IFN) over FU in terms of response rate and
event-free survival, they rightly point to the fact that the
added toxicity and cost and the failure to demonstrate a
survival benefit are not worthy of pursuing this ap-
proach. They cite several studies that have come to the
same conclusion.
Thus, the once exciting story of FU plus a-IFN in
colorectal cancer ends in a disappointment.
This story started with a response rate of 76% in 17
previously untreated patients [14]. It continued with
thousands of patients being treated worldwide by
oncologists who believed in the results. Now, it seems
that many of these patients have suffered for nothing.
This story of FU plus a-IFN should again teach us that
phase II studies are unsuitable tools to reliably detect
the true effect of a treatment: single institution phase n
response rate 76%, multi-institution phase II response
rate 42% [15], multi-institution phase HI response rate
20% [4]. N. Kemeny recently has summarized some of
the reasons for these discrepancies especially in colo-
rectal cancer [7]. Wadlers first paper would have de-
served to be published in the Journal of Irreproducible
Results.
In essence, has there been any progress in the treat-
ment of metastatic colorectal cancer?
The results of the combination of FU with MTX or
FA has shifted the attention towards colorectal cancer
in the medical community. Patients with this disease are
now more likely to receive chemotherapy and benefit in
terms of progression-free and overall survival as com-
pared to no treatment [10,13].
Is there any foreseeable future?
The often cited 'new drugs' do not appear to consid-
erably improve the outcome of metastatic colorectal
cancer. Most of the phase in studies now on the way
intend to show equivalence rather than superiority
compared to FU alone or FU/FA. It is time to realize
that colorectal cancer is a heterogenous disease or else,
552
it is more than one disease. In the same way we are
looking for hormonal receptors in breast cancer, we
need to identify factors in colorectal cancer tissues
which help us to predict treatment outcome like thy-
midylate synthase and p53 [8]. Only then, we can im-
prove the treatment results in one subgroup and spare
the other patients unnecessary side effects.
Prof. R. Herrmann
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